ArticleHuman cell2023

Donor-derived CAR-T therapy improves the survival of relapsed B-ALL after allogeneic transplantation compared with donor lymphocyte infusion.

Zhao Liang et al.PubMed ↗Publisher ↗

No numbers read from the abstract.